ライフサイエンスコーパス: severe combined immunodeficiency

1 kidney capsules of SCID mice (ie, mice with severe combined immunodeficiency).

2 benefits with gene therapy for ADA-deficient severe combined immunodeficiency.

3 ng Tgfb1-null mutant mice on a background of severe combined immunodeficiency.

4 in Matrigel, and formed tumors in mice with severe combined immunodeficiency.

5 ratoma assays in nonobese diabetic mice with severe combined immunodeficiency.

6 c), which is mutated in humans with X-linked severe combined immunodeficiency.

7 ion and subsequently received a diagnosis of severe combined immunodeficiency.

8 logical process defective in human and mouse severe combined immunodeficiency.

9 Amish infant hospitalized in Minnesota with severe combined immunodeficiency.

10 reased sensitivity to ionizing radiation and severe combined immunodeficiency.

11 ression is defective in humans with X-linked severe combined immunodeficiency.

12 ntified in patients with NHEJ deficiency and severe combined immunodeficiency.

13 ngs with T cell, B cell, natural killer cell severe combined immunodeficiency.

14 d kinase, Jak3, are the major cause of human severe combined immunodeficiency.

15 ients display radiosensitivity combined with severe combined immunodeficiency.

16 )), which is mutated in humans with X-linked severe combined immunodeficiency.

17 in humans and null mutations in mice lead to severe combined immunodeficiency.

18 ly, such protection occurred without causing severe combined immunodeficiency.

19 ally attenuated MM tumor growth in mice with severe combined immunodeficiency.

20 inactivated in human radiosensitive T(-)B(-) severe combined immunodeficiency, a syndrome characteriz

21 affected with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) and set out

22 c contrast, 39 adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) patients hav

23 'difficult' conditions [adenosine deaminase-severe combined immunodeficiency (ADA-SCID), major histo

24 ites that destroy the immune system, causing severe combined immunodeficiency (ADA-SCID), often refer

25 clude adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), Shwachman-B

26 s a disorder of purine metabolism leading to severe combined immunodeficiency (ADA-SCID).

27 clinical case of an RSV-infected infant with severe combined immunodeficiency and effectively no adap

28 These features are consistent with the severe combined immunodeficiency and mild extraimmunolog

29 g its goal of defining the true incidence of severe combined immunodeficiency and providing early tre

30 ells injected intraperitoneally (ie, in CB17 severe combined immunodeficiencies) and significantly in

31 , diagnosis of adenosine deaminase-deficient severe combined immunodeficiency, and consanguinity were

32 Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimm

33 g in California established the incidence of severe combined immunodeficiency at 1 in 66,250 live bir

34 ype per heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice.

35 ) were given intranasally or i.p. to newborn severe combined immunodeficiency-beige mice exposed to 9

36 C.B.-17 severe combined immunodeficiency-beige mice were transpl

37 yptosporidium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the par

38 raftment is a common finding in infants with severe combined immunodeficiency but is not typically ob

39 ions in Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, but hypomorphic JAK3 d

40 ete recovery occurred in VLP-dosed mice with severe combined immunodeficiency, but not in wild-type m

41 correct T-cell deficiencies in patients with severe combined immunodeficiency by replacing resident t

42 delivered via osmotic pump in an intratibial severe combined immunodeficiency CAG myeloma model or in

43 eficiency CAG myeloma model or in a systemic severe combined immunodeficiency CAG-heparanase model of

44 Severe combined immunodeficiency can be caused by loss-o

45 ells has emerged as a convincing therapy for severe combined immunodeficiency caused by ILR2G mutatio

46 chain cytokine receptor subunit give rise to severe combined immunodeficiency characterized by lack o

47 Norovirus incidence was compared between severe combined immunodeficiency children with (n = 10)

48 orrection of disease phenotypes for X-linked severe combined immunodeficiency, chronic granulomatous

49 Further, the nonobese diabetic severe combined immunodeficiency common gamma chain knoc

50 was unequivocal evidence that children with severe combined immunodeficiency could be cured by gene

51 Newborn screening for severe combined immunodeficiency detects athymic patient

52 The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and rela

53 BHK tumors growing as xenografts in severe combined immunodeficiency disease (SCID) mice wer

54 n of EBV-CTLs both in vitro and in vivo in a severe combined immunodeficiency disease (SCID) mouse mo

55 wn to lead to an autosomal recessive form of severe combined immunodeficiency disease (SCID).

56 the gene encoding CRACM1 is associated with severe combined immunodeficiency disease in humans.

57 s, whereas transfers into BALB/c x Rag-/- or severe combined immunodeficiency disease mice (H-2d) did

58 ligoclonal lines into either C3H x Rag-/- or severe combined immunodeficiency disease mice (H-2k) als

59 PET experiments were performed in severe combined immunodeficiency disease mice inoculated

60 Patients with severe combined immunodeficiency disease who have matche

61 12 was found to be mutated in patients with severe combined immunodeficiency disease, and expression

62 on mutations found in patients with X-linked severe combined immunodeficiency diseases (X-SCID).

63 d adults with specific forms of PID, such as severe combined immunodeficiency, for over 10 years.

64 ications of anti-CD3epsilon mAb treatment in severe combined immunodeficiency forms characterized by

65 r from healthy donors were injected into NOD-severe combined immunodeficiency gammac(-/-) mice, follo

66 Nonobese diabetic-severe combined immunodeficiency-gammac(-/-) mice were i

67 y CLL cells proliferate in nonobese diabetes/severe combined immunodeficiency/gammac(null) mice under

68 and patients with atypical presentations of severe combined immunodeficiency gene mutations presents

69 treatment advances and newborn screening for severe combined immunodeficiency, has resulted in improv

70 patients with adenosine deaminase deficient severe combined immunodeficiency have identified neutrop

71 HTLV-1-infected humanized nonobese diabetic severe combined immunodeficiency (HU-NOD/SCID) mice were

72 th and prevented bone destruction in vivo in severe combined immunodeficiency-hu mice.

73 Last, treatment of severe combined immunodeficiency-human (SCID-hu) mice wi

74 gnificantly inhibited C4-2B cell growth in a severe combined immunodeficiency-human model of experime

75 homing, and engraftment in nonobese diabetic/severe combined immunodeficiency IL-2gamma(null) (NSG) m

76 HEJ factor ARTEMIS cause radiation-sensitive severe combined immunodeficiency in humans and may incre

77 geneic hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rgamma(nul

78 nstitute immune-deficient (nonobese diabetic/severe combined immunodeficiency/interleukin-2 gammac re

79 Therefore, we created a nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-

80 stitution by transplanting nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-

81 Spontaneously diabetic NOD mice received NOD severe combined immunodeficiency islet transplants and w

82 gene replacement for Hemophilia B, X-linked Severe Combined Immunodeficiency, Leber's Congenital Ama

83 oss of T cells in a spectrum including leaky severe combined immunodeficiency (LS) and Omenn syndrome

84 ndent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05).

85 lial cells, leading to increased survival of severe combined immunodeficiency mice after transplantat

86 (+) fetal liver cells into nonobese diabetic/severe combined immunodeficiency mice allows for the lon

87 n vivo after subcutaneous transplantation in severe combined immunodeficiency mice and differentiated

88 umab and copper-DOTA-conatumumab was done in severe combined immunodeficiency mice bearing Colo205 xe

89 In female CB17 severe combined immunodeficiency mice bearing Colo205 xe

90 ession by PET and ex vivo biodistribution in severe combined immunodeficiency mice bearing H2009 tumo

91 in vivo experiments, 6- to 12-wk-old female severe combined immunodeficiency mice bearing M21 xenogr

92 ol Tyr(4)-BBN: for in vivo GRPR blockade) in severe combined immunodeficiency mice bearing PC-3 xenog

93 d not reduce infectivity or pathogenicity in severe combined immunodeficiency mice but resulted in cl

94 A33 antibodies greatly delayed the deaths of severe combined immunodeficiency mice challenged with va

95 of human erythrocytes into nonobese diabetic/severe combined immunodeficiency mice extends blood circ

96 LL cells transplanted onto nonobese diabetic/severe combined immunodeficiency mice faithfully recapit

97 Finally, YT cells transplanted into severe combined immunodeficiency mice had an invasive be

98 omib significantly prolonged the survival of severe combined immunodeficiency mice inoculated with LC

99 in vivo and pathogenesis are not available, severe combined immunodeficiency mice into which human t

100 myofibers in the injured skeletal muscle of severe combined immunodeficiency mice more effectively t

101 Six nonobese diabetic severe combined immunodeficiency mice received transplan

102 tumor transplantation in Non-obese diabetic/severe combined immunodeficiency mice that the HAGE knoc

103 plantation in xenotolerant nonobese diabetic/severe combined immunodeficiency mice through intrasplen

104 ansplanted nonobese diabetic background with severe combined immunodeficiency mice to assess suppress

105 s (PBMCs) were injected into the footpads of severe combined immunodeficiency mice to measure human d

106 Nonobese diabetic/severe combined immunodeficiency mice transplanted with

107 The tumorigenicity of cells in severe combined immunodeficiency mice was augmented to a

108 Humanized urokinase plasminogen activator/severe combined immunodeficiency mice were used to estab

109 transplanted with MSCs in nonobese diabetic severe combined immunodeficiency mice with a significant

110 antly improved survival of nonobese diabetic/severe combined immunodeficiency mice with HL-60 leukemi

111 ease severity during persistent infection of severe combined immunodeficiency mice with isogenic sero

112 nd decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with P

113 EB-silenced MM cells were then injected into severe combined immunodeficiency mice, and tumor growth

114 In a xenograft analysis of severe combined immunodeficiency mice, cisplatin also ef

115 f human coronary artery were transplanted to severe combined immunodeficiency mice, followed by recon

116 MSCs was not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the im

117 In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of hu

118 esis in immunocompromised non-obese diabetic/severe combined immunodeficiency mice, supporting an onc

119 o a different genogroup, are inoculated into severe combined immunodeficiency mice, the order of seve

120 E. chaffeensis strains were inoculated into severe combined immunodeficiency mice, the order of the

121 ng MDA-MB-231 cell-derived mammary tumors in severe combined immunodeficiency mice, we show here for

122 ro, and suppressed tumor xenograft growth in severe combined immunodeficiency mice.

123 antly inhibited cholangiocarcinoma growth in severe combined immunodeficiency mice.

124 in vitro and in engrafted nonobese diabetic-severe combined immunodeficiency mice.

125 ted in the choroids of six nude rats and six severe combined immunodeficiency mice.

126 otype when transplanted to nonobese diabetic/severe combined immunodeficiency mice.

127 tive transfer, delayed diabetes onset in NOD.severe combined immunodeficiency mice.

128 presses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice.

129 in human PBMC cultures and in PBMC-engrafted severe combined immunodeficiency mice.

130 d into the skeletal muscle of dystrophic mdx/severe combined immunodeficiency mice.

131 g soft agar assays and xenograft analysis of severe combined immunodeficiency mice.

132 x vivo leukemic cells into nonobese diabetic/severe combined immunodeficiency mice.

133 al cavity of streptozotocin-induced diabetic severe combined immunodeficiency mice.

134 ells are tumorigenic in both male and female severe combined immunodeficiency mice.

135 ive, PD-L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice.

136 lanted subcutaneously into nonobese diabetic severe combined immunodeficiency mice.

137 he same day prior to graft implantation into severe combined immunodeficiency mice.

138 ing CD-1 nu/nu and LNCaP tumor-bearing CB-17 severe combined immunodeficiency mice.

139 ppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice.

140 sis utilizing a human CaP xenograft model in severe-combined immunodeficiency mice.

141 SCID (severe combined immunodeficiency) mice underwent left an

142 tudies were performed in Mec-1-bearing SCID (severe combined immunodeficiency) mice, a new animal mod

143 When xenografted into SCID (severe combined immunodeficiency) mice, the expression o

144 s been found in NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice.

145 medulloblastomas in an orthotopic, xenogenic severe combined immunodeficiency model.

146 In human artery-severe combined immunodeficiency mouse chimeras, in whic

147 nd virulence in human skin xenografts in the severe combined immunodeficiency mouse model in vivo.

148 tensively in infected skin xenografts in the severe combined immunodeficiency mouse model of VZV path

149 Using a nonobese diabetic/severe combined immunodeficiency mouse model, those anti

150 bound to BM using both in vitro and in vivo severe combined immunodeficiency mouse models of human M

151 assayable human cells, the nonobese diabetic/severe combined immunodeficiency mouse repopulating cell

152 d engraftment in NOD-SCID (nonobese diabetic-severe combined immunodeficiency) mouse myocardium incre

153 tem with experimental systemic infections of severe combined immunodeficiency Mus musculus with the b

154 tuted with a synthetic LAT gene bearing this severe combined immunodeficiency mutation.

155 under the renal capsule of nonobese diabetic severe combined immunodeficiency (NOD SCID) mice with MS

156 l CD34(+) progenitors into nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice resulte

157 itt lymphoma xenografts in nonobese diabetic/severe combined immunodeficiency (NOD/scid) animals comp

158 Here, we show that nonobese diabetic severe combined immunodeficiency (NOD/SCID) beta(2) micr

159 ition, we demonstrate that nonobese diabetic/severe combined immunodeficiency (NOD/SCID) leukemia-ini

160 aclizumab was evaluated in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice given i

161 cells into immunodeficient nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice leads t

162 th allogeneic T cells into nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice resulte

163 A-overexpressing tumors in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with pa

164 lation assays performed on nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, and in

165 rs when transplanted into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice.

166 (STZ)-induced diabetes in nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice.

167 and after engraftment in a nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse xenogr

168 hat when transplanted into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) recipient mi

169 ere divided into 3 main categories: T(-)B(-) severe combined immunodeficiency, Omenn syndrome, and co

170 ency causes T(-)B(+) natural killer-positive severe combined immunodeficiency or T-cell lymphopenia w

171 mmune system since it did not occur in nude, severe combined immunodeficiency, or T-cell depleted mic

172 ce represent a model for radiation-sensitive severe combined immunodeficiency, our findings suggest t

173 emis nuclease is defective in radiosensitive severe combined immunodeficiency patients and is require

174 h overexpression of Bcl2 does not rescue the severe combined immunodeficiency phenotype in Ku70-defic

175 We describe a pedigree affected by a severe combined immunodeficiency phenotype with absent T

176 A 14-year-old boy with severe combined immunodeficiency presented three times t

177 ons are responsible for the development of a severe combined immunodeficiency [radiation-sensitive (R

178 rchy contains a rare CD34(-) population with severe combined immunodeficiency-repopulating capacity.

179 telangiectasia and a class of Radiosensitive-Severe Combined Immunodeficiency (RS-SCID), respectively

180 function therefore results in radiosensitive severe combined immunodeficiency (RS-SCID).

181 - and B-lymphocyte-independent protection of severe combined immunodeficiency SCID mice from dissemin

182 A subgroup of severe combined immunodeficiencies (SCID) is characteriz

183 fection, wild-type (WT) and C3H animals with severe combined immunodeficiency (SCID animals) were ino

184 success in select diseases such as X-linked severe combined immunodeficiency (SCID) and ADA deficien

185 function of adenosine deaminase (ADA) cause severe combined immunodeficiency (SCID) and affect many

186 n the brain, brain stem, and spinal cords of severe combined immunodeficiency (SCID) and C57BL/6 (wil

187 with ARTEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular rad

188 alues and severely impaired dissemination in severe combined immunodeficiency (SCID) and immunocompet

189 oietic-cell transplantation in children with severe combined immunodeficiency (SCID) and other primar

190 Population-based newborn screening for severe combined immunodeficiency (SCID) and related diso

191 Severe combined immunodeficiency (SCID) and X-linked aga

192 Severe combined immunodeficiency (SCID) arises from diff

193 In a severe combined immunodeficiency (SCID) background, medi

194 sgenic for hHGF/SF (designated hHGF-Tg) on a severe combined immunodeficiency (SCID) background.

195 Severe combined immunodeficiency (SCID) can be cured by

196 Severe combined immunodeficiency (SCID) carries a poor p

197 tivating gene 1 (RAG1) deficiency results in severe combined immunodeficiency (SCID) caused by a comp

198 Severe combined immunodeficiency (SCID) comprises a grou

199 Severe combined immunodeficiency (SCID) comprises a hete

200 to the pathology of Omenn syndrome and leaky severe combined immunodeficiency (SCID) has not been pre

201 The inclusion of severe combined immunodeficiency (SCID) in a Europe-wide

202 in reticular dysgenesis (RD), a rare form of severe combined immunodeficiency (SCID) in humans.

203 Severe combined immunodeficiency (SCID) is a life-threat

204 Early recognition of severe combined immunodeficiency (SCID) is a pediatric e

205 Severe combined immunodeficiency (SCID) is a syndrome of

206 Adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is caused by gen

207 Severe combined immunodeficiency (SCID) is characterized

208 Severe combined immunodeficiency (SCID) is characterized

209 s of galectin-1 were higher in tumor-bearing severe combined immunodeficiency (SCID) mice breathing 1

210 L-6)-dependent human MM cell line INA-6 into severe combined immunodeficiency (SCID) mice previously

211 tumor antigen-specific TCR, we reconstituted severe combined immunodeficiency (SCID) mice with bone m

212 verexpressing SDF-1alpha were xenografted on severe combined immunodeficiency (SCID) mice.

213 th in soft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice.

214 ls within the tumor orthotopic xenografts in severe combined immunodeficiency (SCID) mice.

215 ed p44E was used to infect a naive horse and severe combined immunodeficiency (SCID) mice.

216 cells that can repopulate nonobese diabetic-severe combined immunodeficiency (SCID) mice.

217 he kidney capsule of nonobese diabetic (NOD)-severe combined immunodeficiency (SCID) mice.

218 tiated by transfer of their splenocytes into severe combined immunodeficiency (SCID) mice.

219 Human synovium-severe combined immunodeficiency (SCID) mouse chimeras w

220 In human artery-severe combined immunodeficiency (SCID) mouse chimeras,

221 In human GCA artery-severe combined immunodeficiency (SCID) mouse chimeras,

222 udies using a CD4+CD45Rbhigh T-cell transfer severe combined immunodeficiency (SCID) mouse inflammato

223 ignificant prolonged survival in a xenograft severe combined immunodeficiency (SCID) mouse model of d

224 ed autophagy in human skin xenografts in the severe combined immunodeficiency (SCID) mouse model of V

225 wth of RARalpha2-overexpressing MM tumors in severe combined immunodeficiency (SCID) mouse model.

226 me for at least a month in both nude rat and severe combined immunodeficiency (SCID) mouse xenograft

227 se of nonobese diabetic (NOD) mice, NOD with severe combined immunodeficiency (scid) mutation (SCID)

228 fetal liver cells in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) or NOD/SCID/gamm

229 ic and nonimmunologic outcomes in cohorts of severe combined immunodeficiency (SCID) patients with ei

230 histone H3 recognition were found mutated in severe combined immunodeficiency (SCID) patients.

231 Cl 4 fibrosis were adoptively transferred to severe combined immunodeficiency (SCID) recipients, whic

232 asmid patterns, were infectious in mice with severe combined immunodeficiency (SCID) regardless of th

233 Severe combined immunodeficiency (SCID) represents conge

234 Although gene therapy can cure patients with severe combined immunodeficiency (SCID) syndromes, the c

235 onsortium (PIDTC) is enrolling children with severe combined immunodeficiency (SCID) to a prospective

236 Newborn screening for severe combined immunodeficiency (SCID) using assays to

237 We report here a patient with T(-)B(+)NK(+) severe combined immunodeficiency (SCID) who was homozygo

238 Severe combined immunodeficiency (SCID) with a complete

239 ations that impair Rag2 function can lead to severe combined immunodeficiency (SCID), a condition cha

240 the 91 position found in some patients with severe combined immunodeficiency (SCID), and the double

241 d T-cell reconstitution in many infants with severe combined immunodeficiency (SCID), but correction

242 have been identified, often associated with severe combined immunodeficiency (SCID), consistent with

243 used into young horses (foals) affected with severe combined immunodeficiency (SCID), followed by cha

244 of typical profound T-cell dysfunction (TD), severe combined immunodeficiency (SCID), has been carefu

245 the cervical spinal cords of adult mice with severe combined immunodeficiency (SCID), human pluripote

246 cell transplantation (HCT) for patients with severe combined immunodeficiency (SCID), including survi

247 hly relevant per se because in patients with severe combined immunodeficiency (SCID), infections caus

248 minase (ADA) deficiency, a cause of X-linked severe combined immunodeficiency (SCID), is a case in po

249 t profound primary immunodeficiency disease, severe combined immunodeficiency (SCID), is fatal in inf

250 The most severe form, severe combined immunodeficiency (SCID), presents with p

251 the natural history of patients treated for severe combined immunodeficiency (SCID), Wiskott-Aldrich

252 abrogate lymphocyte development and lead to severe combined immunodeficiency (SCID), XLF mutations c

253 In a severe combined immunodeficiency (SCID)-hu murine model

254 suppressed the growth of MM in vivo using a severe combined immunodeficiency (SCID)-hu murine model.

255 tations in ORAI1 or STIM1 genes present with severe combined immunodeficiency (SCID)-like disease.

256 ion (DRG) xenografts maintained in mice with severe combined immunodeficiency (SCID).

257 population-based newborn screening (NBS) for severe combined immunodeficiency (SCID).

258 cell transplantation (HSCT) in patients with severe combined immunodeficiency (SCID).

259 (HCT) of adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

260 recombination, hence loss of DNA-PK leads to severe combined immunodeficiency (SCID).

261 erleukin-2 gamma-chain receptor (IL2RG)/JAK3 severe combined immunodeficiency (SCID).

262 g immune plasma in young horses (foals) with severe combined immunodeficiency (SCID).

263 in a significant proportion of patients with severe combined immunodeficiency (SCID).

264 ficiency of either Jak3 or gammac results in severe combined immunodeficiency (SCID).

265 nts unable to signal via gammac present with severe combined immunodeficiency (SCID).

266 systemic metabolic disease characterized by severe combined immunodeficiency (SCID).

267 scribe the generation of a marmoset model of severe combined immunodeficiency (SCID).

268 e T- or B-lymphocytes and are diagnosed with severe combined immunodeficiency (SCID).

269 ls (1 Arabian and 1 Arabian-pony cross) with severe combined immunodeficiency (SCID).

270 T-cell development, clinically presenting as severe combined immunodeficiency (SCID).

271 repair pathway result in radiation-sensitive severe combined immunodeficiency (SCID).

272 sies were injected intravenously into C.B-17 severe combined immunodeficiency (SCID)/beige (bg) mice.

273 cured immunodeficiencies including X-linked severe combined immunodeficiency (SCID-X1) and adenine d

274 X-linked severe combined immunodeficiency (SCID-X1) caused by mut

275 X-linked Severe Combined Immunodeficiency (SCID-X1) is a genetic

276 ical trials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney mu

277 fective vectors for gene therapy of X-linked severe combined immunodeficiency (SCID-X1), we have eval

278 ble for use in a clinical trial for X-linked severe combined immunodeficiency (SCID-X1).

279 vector for the correction of canine X-linked severe combined immunodeficiency (SCID-X1).

280 m healthy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1).

281 X-linked severe-combined immunodeficiency (SCID-X1) has been trea

282 sseminating infections in wild-type (WT) and severe-combined-immunodeficiency (SCID) mice was analyze

283 growth in vivo in hairless outbred mice with severe combined immunodeficiency (SHO-Prkdc(scid)Hr(hr))

284 ell lymphopenia, patients with ADA-deficient severe combined immunodeficiency showed a partial block

285 Thus, deficiency of Stat5 results in severe combined immunodeficiency, similar in many respec

286 ations that inactivate Artemis cause a human severe combined immunodeficiency syndrome associated wit

287 chronic inflammation, muscle weakness, and a severe combined immunodeficiency syndrome.

288 established tumors (ie, in nonobese diabetic-severe combined immunodeficiencies) that were derived fr

289 We performed a multicenter survey of severe combined immunodeficiency transplantation centers

290 Recipient mice with severe-combined immunodeficiency underwent retrorsine tr

291 nts with adenosine deaminase (ADA)-deficient severe combined immunodeficiency using 2 slightly differ

292 root ganglion (DRG) xenografts in mice with severe combined immunodeficiency using multiscale correl

293 is with neutrophil infiltration in mice with severe combined immunodeficiency, which is accompanied b

294 natural killer cell-sufficient patient with severe combined immunodeficiency, whom we found had muta

295 r insertion in a clinical trial for X-linked severe combined immunodeficiency (X-SCID) has prompted s

296 of LMO2 following gene therapy for X-linked severe combined immunodeficiency (X-SCID) have led to a

297 X-linked severe combined immunodeficiency (X-SCID) is an immune d

298 liferative disease in three individuals with severe combined immunodeficiency-X1.

299 an restore immunity to infants with X-linked severe combined immunodeficiency (XSCID) caused by mutat

300 Canine X-linked severe combined immunodeficiency (XSCID) is due to mutat